# Percutaneous or Surgical Repair In Mitral Prolapse And Regurgitation for ≥60 Year-olds (PRIMARY)

Study · id `cardio:ct-nct05051033` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05051033](<https://clinicaltrials.gov/study/NCT05051033>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05051033

Browse, organ or system: Heart  
Browse, condition area: Heart failure; Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 450 participants.

## Technical summary

Registry record NCT05051033. Randomized; no masking; primary purpose treatment. Start 2022-02-21 (actual); primary completion 2029-06-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 450 participants (enrolled count; ClinicalTrials.gov record NCT05051033, source copy `cardio:ctgov-nct05051033-2026-10-27`, retrieved 2026-10-31)
- Started: 2022-02-21 (actual) (ClinicalTrials.gov record NCT05051033, source copy `cardio:ctgov-nct05051033-2026-10-27`, retrieved 2026-10-31)
- Primary completion: 2029-06-30 (anticipated) (ClinicalTrials.gov record NCT05051033, source copy `cardio:ctgov-nct05051033-2026-10-27`, retrieved 2026-10-31)
- Completion: 2034-01-31 (anticipated) (ClinicalTrials.gov record NCT05051033, source copy `cardio:ctgov-nct05051033-2026-10-27`, retrieved 2026-10-31)
- Countries: United States; Canada; Germany; Spain; United Kingdom (ClinicalTrials.gov record NCT05051033, source copy `cardio:ctgov-nct05051033-2026-10-27`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05051033-2026-10-27`, retrieved 2026-10-31)

## The registry's words

- Brief title: Percutaneous or Surgical Repair In Mitral Prolapse And Regurgitation for ≥60 Year-olds (PRIMARY)
- Acronym: PRIMARY
- Condition: Mitral Valve Regurgitation
- Intervention (Procedure): Mitral valve repair
- Intervention (Device): Transcatheter edge-to-edge repair
- Lead sponsor: Annetine Gelijns
- Lead sponsor class: OTHER
- Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
- Collaborator class: NIH

## Connected pages

- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry condition terms include this condition: Mitral regurgitation (`cardio:mitral-regurgitation`)
- Registry lists this organization as the lead sponsor: Annetine Gelijns (`cardio:org-annetine-gelijns`)
- Registry lists this organization as a collaborator: National Heart, Lung, and Blood Institute (`cardio:nhlbi`)

## Provenance

Content hash: f9cc220be1c2e91eb26ab0923e42388a0a1265a9f42a0809f8757af1e79c1fc0
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
